



Tuesday, October 20

2009 ACCP Annual Meeting – 30th Anniversary

ORIGINAL RESEARCH

Cardiovascular

16E. Beta-Blocker Evaluation of Survival Trial (BEST) Findings Show Benefit of Bucindolol in Moderate to Severe HF Patients, According to Pre-specified Statistical Analysis Plan.

Bruce R. Koch II, PharmD¹, Eric Eichhorn, MD², Hector Ventura, MD³, Gordon Davis, MSPH¹, Mona Fiuzat, PharmD⁴, Alastair D. Robertson, Ph.D.⁵, Michael R. Bristow, MD, PhD⁶; (1)ARCA biopharma, Inc., Broomfield, CO; (2)Dallas Heart Group, Dallas, TX; (3)Oschner Medical Center, New Orleans, LA; (4)Duke University Medical Center, Division of Clinical Pharmacology, Durham, NC; (5)University of Colorado Health Sciences Center, Denver, CO; (6)ARCA biopharma, University of Colorado Health Sciences Center, Denver, CO

17. Comparison of a Treatment Strategy Using Amlodipine/Valsartan Fixed Dose Combination Therapy (Exforge®) With Conventional Therapy.

Mark A. Malesker, Pharm.D., FCCP, BCPS, Daniel E. Hilleman, Pharm.D., FCCP; Creighton University Medical Center, Omaha, NE

18E. The AGELESS Study: The Effect of Aliskiren vs Ramipril Alone or in Combination With Hydrochlorothiazide and Amlodipine in Patients \geq 65 Years of Age with Systolic Hypertension.

Mark A. Munger, PharmD¹, Daniel A. Duprez, M.D.², Jaco Botha, Ph.D.³, Alan N. Charney, M.D.³; (1)University of Utah, SIC, UT; (2)University of Minnesota Medical School, Minneapolis, MN; (3)Novartis Pharmaceutical Co., East Hanover, NJ

19E. Efficacy of olmesartan medoxomil and hydrochlorothiazide in elderly (\geq 65 years) patients with hypertension: age and gender subgroups.

Dean J. Kereiakes, MD¹, Joel M. Neutel, MD², Kathy A. Stoakes, RN, BSN, CCRA³, William F. Wawerczak, MS³, Jianbo Xu, MS³, Ali Shojaee, PharmD³, Robert Dubiel, PharmD³; (1)The Christ Hospital Heart and Vascular Center and The Carl and Edyth Lindner Center for Research and Education at The Christ Hos, Cincinnati,

OH; (2)Orange County Research Center, Tustin, CA; (3)Daiichi Sankyo, Inc., Parsippany, NJ

20E. Differential effects of nesiritide versus nitroglycerin on inflammatory biomarkers in patients with acute decompensated heart failure.

Sheryl L. Chow, Pharm.D., BCPS¹, Stephen A. O'Barr, PhD¹, Jessica T. Peng, PharmD², Eric E. Chew, PA-C³, Firooz Pak, MD³, Paryus Patel, MD³, Mark P. Okamoto, Pharm.D.¹, J. Herbert Patterson, Pharm.D.⁴, J. Thomas Heywood, MD⁵; (1)Western University of Health Sciences, Pomona, CA; (2)Western University of Health Sciences, College of Pharmacy and Centinela Freeman Regional Medical Center, Pomona, CA, Inglewood, CA; (3)Centinela Hospital, Inglewood, CA; (4)UNC-Chapel Hill, Chapel Hill, NC; (5)Scripps Clinic, La Jolla, CA

21E. Aliskiren Monotherapy Lowers Blood Pressure Independently of Baseline Plasma Renin Activity: Subgroup Analysis of a 6-Month, Double-Blind Trial. *Karl Andersen, MD, PhD¹, Myron H. Weinberger, MD², Christian M. Constance, MD³, Melanie Wright, MSC⁴, Margaret F. Prescott, PhD⁵, Marc Israel, PharmD⁵*; (1)Landspítali University Hospital, Reykjavik, Iceland; (2)Indiana University School of Medicine, Indianapolis, IN; (3)Maisonneuve-Rosemont Hospital, Montreal, QC, Canada; (4)Novartis Pharma AG, Basel, Switzerland; (5)Novartis Pharmaceuticals Corporation, East Hanover, NJ

22. Do statins reduce the incidence of post-operative atrial fibrillation following cardiac valve surgery?.

Kathy M. Makkar, Pharm.D.¹, Janine E. Then, Pharm.D., BCPS², Jill A. Rebuck, Pharm.D., BCPS, FCCP, FCCM¹, Michael A. Horst, PhD, MPH, MS¹, Roy S. Small, M.D., FACC¹, Michael J. Lazar, M.D.², Susan B. Sample, RN, MSN, ACNP-BC¹, Jeffrey T. Cope, M.D., FACS¹; (1)Lancaster General Health, Lancaster, PA; (2)Penn State Milton S. Hershey Medical Center, Hershey, PA

23. Heart failure associated hypervolemia does not cause increased INRs in patients taking warfarin.

Toni Ripley, Pharm.D.¹, Donald Harrison, Pharm.D.¹, Kavita Trivedi, Pharm.D.¹, Robin E. Germany, M.D.², Philip B. Adamson, M.D.³; (1)University of Oklahoma Health Sciences Center, College of Pharmacy, Oklahoma City, OK; (2)University of Oklahoma Health Sciences Center, College of Medicine, Oklahoma City, OK; (3)Oklahoma Foundation for Cardiovascular Research, Heart Failure Institute at the Oklahoma Heart Hospital, Oklahoma City, OK

24E. Diuretic dose is not predictive of worsening renal function in patients with heart failure receiving nesiritide.

Ryan T. Kammer, Pharm.D., David L. Smull, DO; Forsyth Medical Center, Winston-Salem, NC

25E. Safety and tolerability of olmesartan medoxomil and hydrochlorothiazide in elderly (≥ 65 years) patients with stage 1 and stage 2 hypertension.

Joel M. Neutel, MD¹, Deanna Cheung, MD², Kathy A. Stoakes, RN, BSN, CCRA³, William F. Wawerczak, MS³, Jianbo Xu, MS³, Ali Shojaee, PharmD³, Robert Dubiel, PharmD³; (1)Orange County Research Center, Tustin, CA; (2)Long Beach Center for Clinical Research, Long Beach, CA; (3)Daiichi Sankyo, Inc., Parsippany, NJ

26E. Efficacy of olmesartan medoxomil and hydrochlorothiazide in elderly (≥ 65 years) patients with hypertension as assessed by ambulatory blood pressure monitoring.

Dean J. Kereiakes, MD¹, Jaime Sandoval, MD², Deanna Cheung, MD³, Kathy A. Stoakes, RN, BSN, CCRA⁴, William F. Wawerczak, MS⁴, Jianbo Xu, MS⁴, Ali Shojaee, PharmD⁴, Robert Dubiel, PharmD⁴; (1)The Christ Hospital Heart and Vascular Center and The Carl and Edyth Lindner Center for Research and Education at The Christ Hos, Cincinnati, OH; (2)Padre Coast Clinical Research, Corpus Christi, TX; (3)Long Beach Center for Clinical Research, Long Beach, CA; (4)Daiichi Sankyo, Inc., Parsippany, NJ

27E. Effect of Age, Gender, Race and Ethnicity On Efficacy of Amlodipine/Valsartan/Hydrochlorothiazide Triple Combination Therapy in Patients with Moderate to Severe Hypertension.

David Calhoun, MD¹, Robert Glazer, MD², Joseph Yen, PhD², Yves Lacourciere, MD, FRCPC, FACP³; (1)University of Alabama at Birmingham, Birmingham, AL; (2)Novartis Pharmaceuticals Corporation, East Hanover, NJ; (3)Centre Hospitalier de l'Universite Laval,, Sainte Foy, QC, Canada

28E. Effect of Prescription Omega-3 Fatty Acids coadministered with escalating doses of atorvastatin on non-HDL-C in patients with hypertriglyceridemia.

Harold E. Bays, MD, FACP, FACE¹, James J. McKenney, PharmD², Ralph Doyle, BA³, Roderick N. Carter, MD³, Evan A. Stein, MD, PhD, FRCP(C), FCAP⁴; (1)Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY; (2)School of Pharmacy, National Clinical Research, Inc, Richmond, VA; (3)Reliant Pharmaceuticals, Inc., Liberty Corner, NJ; (4)Metabolic and Atherosclerosis Research Center, Cincinnati, OH

30E. Effect of Baseline Systolic Blood Pressure On Response to Triple Combination Amlodipine/Valsartan/Hydrochlorothiazide in Patients with Moderate-to-Severe Hypertension.

Yves Lacourciere, MD, FRCPC, FACP¹, Robert Glazer, MD², Nora Crikelair, PhD², Joseph Yen, PhD², David Calhoun, MD³; (1)Centre Hospitalier de l'Universite Laval,, Sainte Foy, QC, Canada; (2)Novartis Pharmaceuticals Corporation, East Hanover, NJ; (3)University of Alabama at Birmingham, Birmingham, AL

31E. Twenty-Four Hour Ambulatory BP Control of Therapy with Amlodipine/Valsartan/Hctz Triple Combination Compared to Dual Therapy in Patients with Moderate to Severe Hypertension.

Yves Lacourciere, MD, FRCPC, FACP¹, Robert Glazer, MD², Joseph Yen, PhD², David Calhoun, MD³; (1)Centre Hospitalier de l'Universite Laval,, Sainte Foy, QC, Canada; (2)Novartis Pharmaceuticals Corporation, East Hanover, NJ; (3)University of Alabama at Birmingham, Birmingham, AL

32. Coronary Artery Bypass Graft Surgery and Bleeding Outcomes with Recent Clopidogrel Exposure.

Charles H. Hayes III, Pharm.D., Danielle Blais, Pharm.D., Michael Firstenberg, M.D., Kerry K. Pickworth, Pharm.D.; The Ohio State University Medical Center, Columbus, OH

33. Platelet response to aspirin in healthy volunteers.

Rebecca D. Moote, PharmD, BCPS, Laurajo Ryan, PharmD, MSc, BCPS, CDE, Christopher R. Frei, PharmD, MS, BCPS, Robert L. Talbert, PharmD, FCCP, BCPS, FAHA; University of Texas at Austin and University of Texas Health Science Center at San Antonio, San Antonio, TX

34. Evaluation of postoperative atrial fibrillation in patients undergoing cardiac surgery.

Wesley R. Zemrak, Pharm.D., Danielle M. Blais, Pharm.D., Kerry K. Pickworth, PharmD; The Ohio State University Medical Center, Columbus, OH

35E. Colesevelam's Effect on Lipid Parameters in Monotherapy or Combination Therapy: A Meta-analysis.

Julie M. Strickland, Pharm.D.¹, Daniel M. Riche, Pharm.D., BCPS, CDE², Krista D. Riche, Pharm.D., BCPS³, Honey E. East, M.D.⁴; (1)University of Mississippi School of Pharmacy, Jackson, MS; (2)University of Mississippi Schools of Pharmacy and Medicine, Jackson, MS; (3)Mississippi Baptist Medical Center, Jackson, MS; (4)University of Mississippi School of Medicine, Jackson, MS

36E. Decreased hospital readmission with nitroprusside in acute decompensated heart failure.

Anne P. Spencer, PharmD, BCPS¹, Robert L. Page III, PharmD, MHA, BCPS², Adrian Van Bakel, MD, PhD³; (1)Roper Saint Francis Healthcare, Charleston, SC;

(2)University of Colorado School of Pharmacy, Denver, CO; (3)Medical University of South Carolina, Charleston, SC

37E. Modified Clopidogrel Desensitization Following Percutaneous Coronary Intervention (PCI): A Novel Approach to the Management of Clopidogrel Allergy. *Denis Brouillette, B.Pharm, D.P.H.*; Montreal Heart Institute, Montreal, QC, Canada

Critical Care

38E. Nicardipine in the Management of Hypertension in Critically Ill Patients.

Mark A. Malesker, Pharm.D., FCCP, BCPS, Robyn R. Kondrack, Pharm.D., Daniel E. Hilleman, Pharm.D., FCCP; Creighton University Medical Center, Omaha, NE

39E. Economic impact of dexmedetomidine vs. midazolam in adult ICU patients with prolonged mechanical ventilation: An economic model.

*Joseph Dasta, M.Sc.*¹, Paula Bokesch, MD², Sandra L. Kane-Gill, PharmD, MSc³, Michael Pencina, PhD⁴, Richard Riker, MD⁵; (1)The University of Texas College of Pharmacy, Austin, TX; (2)Hospira, Inc, Lake Forest, IL; (3)University of Pittsburgh, Pittsburgh, PA; (4)Boston University, Boston, MA; (5)Maine Medical Center, Portland, ME

40. Modification of Diet in Renal Disease, Modified Crockroft-Gault and 24-urine formulas are poor predictors of aminoglycoside elimination in critically ill surgical patients.

Anthony Gerlach, PharmD, BCPS, Claire V. Murphy, PharmD, Stanislaw Stawicki, MD, Charles H. Cook, MD; The Ohio State University Medical Center, Columbus, OH

42. Pharmacokinetics of enoxaparin following subcutaneous and intravenous administration in critically ill trauma patients.

*Curtis E. Haas, Pharm.D.*¹, Krishnan Raghavendran, M.D.², Alan Forrest, Pharm.D.³, Edward Timm, Pharm.D.⁴, Charles W. Francis, M.D.⁵; (1)University of Rochester Medical Center, Rochester, NY; (2)University of Michigan Health Systems, Ann Arbor, MI; (3)University at Buffalo, Buffalo, NY; (4)Albany Medical Center, Albany, NY; (5)University of Rochester, School of Medicine and Dentistry, Rochester, NY

43. Review of Colloid Utilization IN Cardiac Surgery.

Denis Brouillette, B.Pharm, D.P.H., Nicolas Noël, B.Pharm, M.Sc, Sylvain Belisle, MD, Jean-Sebastien Lebon, MD; Montreal Heart Institute, Montreal, QC, Canada

Education/Training

44. Assessment of pharmacy student's ability to critique drug advertisements.

Terri M. Wensel, Pharm.D., Maisha K Freeman, Pharm.D., BCPS, Mary R Monk-Tutor, Ph.D., R.Ph., FASHP; Samford University McWhorter School of Pharmacy, Birmingham, AL

45. Reliability of a seminar grading rubric in a grand rounds course.

*Eric J. MacLaughlin, Pharm.D.*¹, David S. Fike, Ph.D.¹, Carlos A. Alvarez, Pharm.D.², Charles F. Seifert, Pharm.D.³, Amie T. Blaszczyk, Pharm.D.²; (1)Texas Tech University Health Sciences Center School of Pharmacy, Amarillo, TX; (2)Texas Tech University Health Sciences Center School of Pharmacy, Dallas, TX; (3)Texas Tech University Health Sciences Center School of Pharmacy, Lubbock, TX

46. Assessing pharmacy students' beliefs and confidence levels before and after an elective course in infectious diseases.

Elias B. Chahine, PharmD, BCPS, Allana J. Sucher, PharmD, BCPS, Adwoa O. Nornoo, PhD; Palm Beach Atlantic University, West Palm Beach, FL

47. Curriculum in pharmacogenetics and pharmacogenomics in colleges and schools of pharmacy in the United States.

*Laura Adams, Pharm.D.*¹, Robert Squire, Pharm.D.¹, John E. Murphy, Pharm.D.¹, James Green, Pharm.D.²; (1)The University of Arizona College of Pharmacy, Tucson, AZ; (2)Shenandoah University Bernard J. Dunn School of Pharmacy, Ashburn, VA

48. Constructing a tool to assess deep student learning within advanced pharmacy practice experiences.

Danny McNatty, Pharm.D., BCPS¹, Michael J. Peeters, PharmD, MEd, BCPS², *Samatha Karr, Pharm.D., BCPS*³; (1)Midwestern University College of Pharmacy - Glendale, Glendale, AZ; (2)University of Toledo College of Pharmacy, Toledo, OH; (3)Midwestern University College of Pharmacy, Glendale, AZ

49. Development and implementation of an internal educational needs assessment for hospital pharmacists in an academic medical center.

Rebecca A. Taylor, Pharm.D., MBA, BCPS, Jun-Yen Yeh, Ph.D., *Morton P. Goldman, Pharm.D., FCCP, BCPS*; Cleveland Clinic, Cleveland, OH

50. Experience-based pharmacist education needs assessment in an academic medical center.

Jun-Yen Yeh, Ph.D., Rebecca A. Taylor, Pharm.D., MBA, BCPS, Morton P. Goldman, Pharm.D., FCCP, BCPS; Cleveland Clinic, Cleveland, OH

51. Comparing Colleges' of Pharmacy didactic migraine education to the U.S. Headache Consortium's evidence-based migraine treatment guidelines.

Richard G. Wenzel, Pharm.D.¹, *Rosalyn S. Padiyara, Pharm.D., CDE*², Jon C. Schommer, Ph.D.³; (1)Diamond Headache Clinic Inpatient Unit, Chicago, IL; (2)Midwestern University - Chicago College of Pharmacy, Downers Grove, IL; (3)Department of Pharmaceutical Care and Health Systems, Minneapolis, MN

53. Pharmacy students' work experience.

Michael Steinberg, PharmD, Anna K Morin, PharmD; Massachusetts College of Pharmacy and Health Sciences, Worcester, MA

54. Impact of an online self-paced lecture to deliver drug information.

Suzanne G. Bollmeier, PharmD, BCPS, AE-C, Alicia B. Forinash, Pharm.D., BCPS, Philip J. Wenger, Pharm.D., BCPS; St. Louis College of Pharmacy, Saint Louis, MO

55. Impact of online lecture viewing on student attendance in a therapeutics course.

Suzanne G. Bollmeier, PharmD, BCPS, AE-C, Philip J Wenger, Pharm.D., BCPS, Alicia B Forinash, Pharm.D., BCPS; St. Louis College of Pharmacy, Saint Louis, MO

56. Implementation of "living with diabetes week" curriculum and its impact on student attitude related to diabetes.

Deirdre E. Delea, Pharm, D, Sarah Shrader, Pharm D, BCPS, CDE; Medical University of South Carolina, Summerville, SC

57. Pre-APPE assessment of students' clinical writing skills in a capstone course.

*Jeannine M. Conway, PharmD*¹, Michael C. Brown, Pharm.D.²; (1)University of Minnesota, Minneapolis, MN; (2)Concordia University Wisconsin, Mequon, WI

58. Impact of on-line lecture viewing on student outcomes.

Suzanne G. Bollmeier, PharmD, BCPS, AE-C, Philip J Wenger, Pharm.D., BCPS, Alicia B. Forinash, Pharm.D., BCPS, CCD; St. Louis College of Pharmacy, Saint Louis, MO

59. Assessing the Progression of Pharmacy Student Achievement of the Center for the Advancement of Pharmaceutical Education (CAPE) outcomes in a senior capstone course.

*Jennifer L. Donovan, PharmD*¹, Abir O. Kanaan, Pharm.D.¹, Evan R. Horton, PharmD¹, Cheryl Abel, PharmD², Paul Belliveau, PharmD, RPh¹, Matthew A. Silva, Pharm.D., BCPS¹; (1)Massachusetts College of Pharmacy and Health Sciences, Worcester, MA; (2)Mass College of Pharmacy and Health Sciences, Worcester, MA

60. Relationship between faculty self assessments and students ratings of learner centered teaching during advanced pharmacy experiences.

Anna K. Morin, PharmD, Abir Kanaan, PharmD, Matt Silva, PharmD, Paul Belliveau, PharmD; MCPHS, Worcester, MA

61. Survey of the early entry program's influence on pharmacy student development.

Lauren S. Bloodworth, PharmD, BCPS, T. Kristopher Harrell, PharmD, Alicia Bouldin, PhD; University of Mississippi School of Pharmacy, Jackson, MS
Survey of the Early Entry Program's Influence on Pharmacy Student Development. Lauren S. Bloodworth, Alicia S. Bouldin, and T. Kristopher Harrell. The University of Mississippi.

Emergency Medicine

62. Drug Information References Used by Emergency Medicine Clinicians to Make Prescribing Decisions to Pregnant Patients.

Lindsay Stansfield, Pharm.D., *Victor Cohen, Pharm.D.*, Samantha Jellinek, Pharm.D., Antonios Likourezos, MA., MPH.; Maimonides Medical Center, Brooklyn, NY yet 40 (66%) of the most commonly utilized drugs in

63. Effect of sedative and paralytic dosing on first attempt success rate during rapid sequence intubation in the emergency department.

*Sara A. Stahle, Pharm.D.*¹, Asad E. Patanwala, Pharm.D.¹, Daniel P. Hays, Pharm.D.², John C. Sakles, M.D.³, Brian L. Erstad, Pharm.D.¹; (1)The University of Arizona College of Pharmacy, Tucson, AZ; (2)University Medical Center, Tucson, AZ; (3)The University of Arizona College of Medicine, Tucson, AZ

Health Services Research

75. Formation of a nationwide clinical pharmacist practice-based research network.

*Grace M. Kuo, Pharm.D., M.P.H.*¹, Jacqueline S. Marinac, Pharm.D.²; (1)UCSD and ACCP, La Jolla, CA; (2)ACCP Research Institute, Lenexa, KS

Infectious Diseases

95. Effect of renal function on the pharmacodynamics of piperacillin/tazobactam administered by intermittent and prolonged infusion.

S. Christian Cheatham, Pharm.D.¹, Katherine M. Shea, Pharm.D.², Matthew F. Wack, M.D.³, David W. Smith, Pharm.D.⁴, Kevin M. Sowinski, Pharm.D.⁵, *Michael B. Kays, Pharm.D.*⁵; (1)St. Francis Hospitals and Health Centers, Beech Grove, IN; (2)University Medical Center at Brackenridge, Austin, TX; (3)Infectious Diseases of Indiana, Indianapolis, IN; (4)Clarian Health Partners, Inc.,

Methodist Hospital, Indianapolis, IN; (5)Purdue University School of Pharmacy, Indianapolis, IN

96. Association of Vancomycin Trough Concentrations and Nephrotoxicity.

Julia Munsch, Pharm.D.¹, Jason Ellison, Pharm.D.¹, Nam Nguyen, Pharm.D.¹, Cinda Christensen, Pharm.D., BCPS-ID¹, *Jenana Halilovic, Pharm.D., BCPS²*; (1)UC Davis Medical Center, Sacramento, CA; (2)University of the Pacific T.J.L. School of Pharmacy and Health Sciences, Stockton, CA

97E. Risk Factors for Extended Spectrum β Lactamase-Producing *Klebsiella Pneumoniae* (ESBL): a Focus on Previous Antibiotic Exposure (PAE).

Suprat Saely, PharmD¹, Keith S. Kaye, MD², Marilyn Fairfax, PhD², Teena Chopra, MD², Jason M. Pogue, PharmD¹; (1)Sinai-Grace Hospital, Detroit Medical Center, Detroit, MI; (2)Detroit Medical Center/Wayne State University, Detroit, MI

98E. Successful utilization of a prolonged course of nitazoxanide for the treatment of multi-recurrent *Clostridium difficile* infection.

Matthew Bardin, PharmD, BCPS¹, Bienvenido Yangco, MD, MPH²; (1)Romark Institute for Medical Research, Tampa, FL; (2)Infectious Disease Research Institute, Inc, Tampa, FL

99E. In vitro susceptibility of doripenem versus imipenem against acinetobacter baumannii and pseudomonas aeruginosa in a 4-hospital system.

Hope T. Le, Pharm.D., Daniel Keays, M.S., C.L.S., Gonzalo Ballon-Landa, M.D., Harminder Sikand, Pharm.D.; Scripps Mercy Hospital, San Diego, CA

100E. Efficacy and safety of doripenem (DORI) versus comparators (COMP) in subjects with Acinetobacter baumannii: integrated analysis of six phase III clinical studies.

Janet A. Peterson, PhD¹, Zhihai Qin, PhD¹, Alan C. Fisher, DrPH¹, *Susan C. Nicholson, MD¹*, Jörg Laeuffer, MD²; (1)Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, NJ; (2)Janssen-Cilag, Baar, Switzerland

101E. Clinical outcome of nosocomial pneumonia (NP)/ventilator-associated pneumonia (VAP), or health-care associated pneumonia (HAP) after treatment with doripenem (DORI) 1g infused over 4 hours (h) every 8 hours (Q8H) in a study that enriched for infection with

Mary Ambruzs, RN, BSN, June Sambrowski, RN, Simrati Kaul, PhD, Mohammed Khashab, PhD, Jim Xiang, PhD, Janet A. Peterson, PhD, *Susan C. Nicholson, MD*; Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, NJ

102. Clinical Experience with Daptomycin for the Treatment of Methicillin-Susceptible Staphylococcus aureus (MSSA).

Marianne Billeter, PharmD, BCPS¹, Joseph J. Kishel, PharmD², Ellie Hershberger, PharmD², Katie Holloway, PharmD²; (1)Ochsner Clinic Foundation, New Orleans, LA; (2)Cubist, Lexington, MA

104. Comparative sensitivity testing of Escherichia coli and Pseudomonas aeruginosa isolates from El Paso, Texas and Ciudad Juarez, Mexico.

José O. Rivera, Pharm.D.¹, Hoi Ho, MD², Sureh Antony, MD², Alan H. Tyroch, MD², Melchor Ortiz, PhD²; (1)University of Texas at El Paso and University of Texas at Austin, El Paso, TX; (2)Texas Tech University HSC, Paul L. Foster School of Medicine at El Paso, El Paso, TX

105. Do standard β -lactam dosing regimens achieve pharmacodynamic targets in hospitalized patients with faster creatinine clearances?

Michael B. Kays, Pharm.D.¹, S. Christian Cheatham, Pharm.D.², Katherine M. Shea, Pharm.D.³, David W. Smith, Pharm.D.⁴, Matthew F. Wack, M.D.⁵, Kevin M. Sowinski, Pharm.D.¹; (1)Purdue University School of Pharmacy, Indianapolis, IN; (2)St. Francis Hospitals and Health Centers, Beech Grove, IN; (3)University Medical Center at Brackenridge, Austin, TX; (4)Clarian Health Partners, Inc., Methodist Hospital, Indianapolis, IN; (5)Infectious Diseases of Indiana, Indianapolis, IN

106. An antimicrobial stewardship restriction protocol optimizes the use of daptomycin.

Elizabeth B. Hirsch, PharmD¹, Jaye S. Weston, RPh¹, Jessica M. Cottreau, PharmD², Kevin W. Garey, PharmD², Vincent H. Tam, PharmD², Hannah R. Palmer, PharmD¹; (1)St. Luke's Episcopal Hospital, Houston, TX; (2)University of Houston College of Pharmacy, Houston, TX

107E. Susceptibility of baseline Pseudomonas aeruginosa and Acinetobacter baumannii to doripenem and other antibiotics from six doripenem phase 3 clinical trials.

Koné Kaniga, MD, Rebecca Redman, MD, Ian Friedland, MD, Alvaro Quintana, MD; Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ

108E. Doripenem clinical and microbiologic outcomes by baseline susceptibility for Pseudomonas aeruginosa and Acinetobacter baumannii from 5 phase 3 clinical trials.

Koné Kaniga, MD, Rebecca Redman, MD, Nzeera Ketter, MD, Obiamiwe Umeh, MD, Shin-Yir Tong, MS, Michael Lee, PhD, Ian Friedland, MD; Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ

109E. Coordinate regulation of *ERG11* and *UPC2* in azole resistant isolates of *Candida albicans*.

Stephanie A. Flowers, Pharm.D., Katherine S. Barker, Ph.D., P. David Rogers, Pharm.D, Ph.D., FCCP; University of Tennessee, Memphis, TN

110. Up-regulated genes of the ergosterol biosynthesis pathway associated with azole antifungal resistance in clinical isolates of *Candida albicans*.

Stephanie A. Flowers, Pharm.D., Katherine S. Barker, Ph.D., P. David Rogers, Pharm.D., Ph.D., FCCP; University of Tennessee, Memphis, TN

111E. In vitro activity of colistin in combination with ceftazidime, ceftriaxone, clarithromycin, imipenem, linezolid and vancomycin against metallo-beta-lactamase *Acinetobacter baumannii*.

David S. Burgess, Pharm.D, FCCP, Warunee Srisuphalarn, Pharm.D, Michael F. Carden, BA; University of Texas Health Science Center San Antonio, San Antonio, TX

112E. Susceptibility profile of colistin-susceptible and colistin-resistant *A. baumannii* to several antibiotics.

David S. Burgess, Pharm.D, FCCP, Warunee Srisuphalarn, Pharm.D; University of Texas Health Science Center San Antonio, San Antonio, TX

113E. Impact of dosing strategies on the killing of multi-drug resistant-*Acinetobacter baumannii* with colistin and amikacin in combination using a pharmacokinetic-pharmacodynamic model.

David S. Burgess, Pharm.D, FCCP, Russell T. Attridge, Pharm.D, Warunee Srisuphalarn, Pharm.D; University of Texas Health Science Center San Antonio, San Antonio, TX

114E. Effects of gain-of-function mutations in *PDR1* on fluconazole resistance and global gene expression in *Candida glabrata*.

Kelly E. Caudle, Pharm.D.¹, Nathan P. Wiederhold, Pharm.D.², Kathy S. Barker, Ph.D.¹, P. David Rogers, Pharm.D., Ph.D.¹; (1)University of Tennessee Health Science Center, Memphis, TN; (2)The University of Texas Health Science Center at San Antonio, San Antonio, TX

115. Comparison of treatment efficacy with metronidazole monotherapy or metronidazole and oral vancomycin for *Clostridium difficile* associated diarrhea (CDAD).

Christopher J. Destache, Pharm.D., FCCP¹, Melissa Lopic, Pharm. D.¹, Stephen Cavalieri, Ph., D.²; (1)Creighton University School of Pharmacy and Health Professions, Omaha, NE; (2)Creighton University Medical Center, Omaha, NE

116E. CANVAS-1: randomized, double-blinded, phase 3 study (p903-06) of the efficacy and safety of ceftaroline vs

vancomycin plus aztreonam in complicated skin and skin structure infections.

G. Ralph Corey, MD¹, Mark Wilcox, BMedSci, BMBS, MD², Tanya Baculik, MD³, Dirk Thye, MD³, Joseph Laudano, PharmD⁴; (1)Duke Clinical Research Institute and Duke University Medical Center, Durham, NC; (2)Leeds Teaching Hospitals NHS Trust / University of Leeds, Leeds, United Kingdom; (3)Cerexa, Inc, Oakland, CA; (4)Forest Research Institute, Jersey City, NJ

117. Prior Vancomycin Exposure and its Impact on Vancomycin MIC in Patients with MRSA Pneumonia.

Jack Brown, Pharm, D, MS, BCPS¹, Kristen Brown, MSN², Elizabeth Dodds Ashley, PharmD, MHS, BCPS², Robert Betts, MD², Fred Doloresco, Pharm, D, MS¹, Smita Kothari, PhD, MBA, RPh³; (1)State University of New York at Buffalo, Buffalo, NY; (2)University of Rochester Medical Center, Rochester, NY; (3)Astellas Pharma, Deerfield, IL

118. Assessing the impact of an antimicrobial allergy label in the medical record on patient's clinical course.

Gaurav Deshpande, Doctoral, Candidate¹, Lisa Charneski, PharmD, BCPS², Sheila Weiss, Ph.D.¹, Angela Wilks, Ph.D.³; (1)Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD; (2)Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Rockville, MD; (3)Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD

119E. Bactericidal activity of ceftaroline combined with NXL-104 against critical targeted organisms possessing various resistance mechanisms.

Helio S. Sader, MD, PhD¹, Gregory Williams, MD², Ian Critchley, PhD², Joseph Laudano, PharmD³, Ronald N. Jones, MD¹; (1)JMI Laboratories, North Liberty, IA; (2)Cerexa, Inc., Oakland, CA; (3)Forest Research Institute, Jersey City, NJ

120. Methicillin-Resistant *Staphylococcus aureus* (MRSA) Strain Characteristics Predictive of Mortality in Bloodstream Infections.

Paulina Deming, Pharm.D., Brian Werth, PharmD candidate, Melinda Montoya, PharmD candidate, Chris Werth, PharmD, Jora Sliwinski, PharmD candidate, George Sakoulas, MD, Steve Young, PhD, Renee-Claude Mercier, PharmD; University of New Mexico Health Sciences Center, Albuquerque, NM

121. Evaluation of risk factors associated with invasive candidiasis in critically ill infants.

Mike K. Wang, PharmD¹, Lupe Padilla, MD¹, Tina Song, PharmD¹, Jennifer Le, PharmD, BCPS-ID²; (1)Miller

Children's Hospital, Long Beach, CA; (2)UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA

122. Mandatory MRSA surveillance and absence of reduction in MRSA infection rates.

*Sheila K. Wang, Pharm.D.*¹, Anne M. Sadofsky, Pharm.D., candidate¹, Marc Scheetz, Pharm.D., MSc, BCPS¹, Thomas J. Reutzel, Ph.D., M.S., B.A.¹, Meghana Aruru,¹ Bala N. Hota, MD, MPH², Kamal Singh, MD³; (1)Midwestern University, Chicago College of Pharmacy, Downers Grove, IL; (2)Stroger Hospital of Cook County/Rush University Medical Center, Chicago, IL; (3)Rush University Medical Center, Chicago, IL

123E. Erroneous Reporting of Extended-Spectrum Beta-lactamase Producers from Vitek2 and BD Phoenix Automated Systems.

*Natalie Boyd, Pharm.D., M.S.*¹, Renee C. Mercier, Pharm.D.¹, Clifford Gaylor, BS², David S. Burgess, PharmD, FCCP³, Paul Schreckenberger, Ph.D.⁴, Steve Young, Ph.D.²; (1)University of New Mexico Health Sciences Center, Albuquerque, NM; (2)Tricore Reference Laboratories, Albuquerque, NM; (3)University of Texas Health Science Center San Antonio, San Antonio, TX; (4)University of Illinois Medical Center at Chicago, Chicago, IL

124. Successful treatment of vancomycin-resistant *Enterococcus faecium* meningitis with high-dose daptomycin.

*P. Brandon Bookstaver, PharmD, BCPS, AAHIVE*¹, Celeste N. Rudisill, PharmD¹, Mohammed Hashem, PharmD, Candidate¹, Phillip Yeon, MD²; (1)South Carolina College of Pharmacy-USC Campus, Columbia, SC; (2)Palmetto Health Richland, Columbia, SC

125E. Misidentification of *Klebsiella pneumoniae* carbapenemases as Extended Spectrum Beta-lactamase producers by Automated Testing Instruments.

*Natalie Boyd, Pharm.D., M.S.*¹, Renee C. Mercier, Pharm.D.¹, David S. Burgess, PharmD, FCCP², Paul Schreckenberger, Ph.D.³, Kamal Singh, MD⁴; (1)University of New Mexico Health Sciences Center, Albuquerque, NM; (2)University of Texas Health Science Center San Antonio, San Antonio, TX; (3)University of Illinois Medical Center at Chicago, Chicago, IL; (4)Rush University Medical Center, Chicago, IL

126. In vitro Activity of Carbapenems (CARBs) Alone and In Combination with Amikacin (AMK) Against Extended-Spectrum Beta-Lactamase (ESBL)-Producing Bacteria with Reduced CARB Susceptibility (S).

*Jennifer Le, PharmD, BCPS-ID*¹, Ronald N. Jones, MD², Mariana Castanheira, PhD², Warunee Srisupha-olarn, PharmD³, David S. Burgess, PharmD, FCCP³; (1)University of California San Diego, Skaggs School of

Pharmacy and Pharmaceutical Sciences, La Jolla, CA; (2)JMI Laboratories, North Liberty, IA; (3)University of Texas Health Science Center, San Antonio, TX

Pharmacokinetics/Pharmacodynamics/Drug

177. The effect of serum Albumin on Methotrexate Level Variability and Methotrexate toxicity.

Sherif Kamal, BSC; Children Cancer Hospital Cairo, Cairo, Egypt

178. Pharmacokinetics of mycophenolate and its glucuronidated metabolites in stable islet transplant recipients.

*Mai Al-Khatib, BSc(Pharm), MSc(Pharm)*¹, R. Jean Shapiro, MD, FRCPC², Nilufar Partovi, BSc(Pharm), PharmD³, Lillian S. L. Ting, BSc, MSc, PhD¹, *Mary HH Ensom, PharmD, FASHP, FCCP, FCSHP, FCAHS*⁴; (1)University of British Columbia, Vancouver, BC, Canada; (2)University of British Columbia, Vancouver General Hospital, Vancouver; (3)University of British Columbia and Vancouver General Hospital, Vancouver, BC, Canada; (4)University of British Columbia, Children's & Women's Health Centre of British Columbia, Vancouver, BC, Canada

180. Outcomes of the implementation of an area under the curve/minimum inhibitory concentration vancomycin nomogram.

*Cristy L. Pounders, Pharm.D.*¹, Sarah J. Hollis, Pharm.D.², Elizabeth L. Michalets, Pharm.D., BCPS, CPP², John D. Phillips, Pharm.D.², Susan E. Sutherland, PhD²; (1)Methodist University Hospital, Memphis, TN; (2)Mission Hospitals, Asheville, NC

181E. A Population Pharmacokinetic Analysis for Aripiprazole in Children and Adolescents Ages 10-17.

*Sarah Marston, PhD*¹, Robert L. Findling, M.D.², Suresh Mallikaarjun, PhD¹, Taro Iwamoto, PhD³, William Carson, MD³, Andrei Pikalov, MD, PhD⁴, *Carlos Rojas-Fernandez, PharmD, BCPP*⁵, Quynh-Van Tran, PharmD, BCPP⁴; (1)Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD; (2)University Hospitals Case Medical Center, Cleveland, OH; (3)Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; (4)Otsuka America Pharmaceutical, Inc, Rockville, MD; (5)Bristol-Myers Squibb, Plainsboro, NJ

182E. Pharmacokinetics of doripenem in subjects with varying degrees of renal impairment.

Iolanda Cirillo, MS, Nicole Vaccaro, BS, Hong Tian, PhD, Bibiana Castaneda-Ruiz, MD, Kenneth Turner, PhD, Rebecca Redman, MD; Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ

183E. Effects of age and gender on doripenem pharmacokinetics.

Kenneth Turner, PhD, Iolanda Cirillo, MS, *Nicole Vaccaro, BS*, Bhavna Solanki, PhD, Rebecca Redman, MD; Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ

184E. Pharmacokinetics of doripenem 1g administered over 4 hours in patients with ventilator associated pneumonia.

Nicole Vaccaro, BS, Rebecca Redman, MD, Iolanda Cirillo, MS; Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ

185E. Pharmacokinetics of doripenem in chronic HD subjects during CRRT.

Iolanda Cirillo, MS, *Nicole Vaccaro, BS*, Rosemary Evans, MD, Rebecca Redman, MD; Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ

186E. Pharmacokinetics of doripenem in adults with cystic fibrosis.

Iolanda Cirillo, MS¹, *Nicole Vaccaro, BS¹, Rosemary Evans, MD¹, Rebecca Redman, MD¹, Gregory L. Kearns, PharmD, PhD²; (1)Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ; (2)Children's Mercy Hospitals and Clinics, Kansas City, MO*

187E. The Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in patients with rheumatoid arthritis and lupus nephritis.

*Tomonori Nakamura, PhD*¹, Yuko Okada, PhD², Keiju Hiromura, MD, PhD¹, Yoshihisa Nojima, MD, PhD¹, Katsunori Nakamura, PhD¹, Koujirou Yamamoto, PhD¹; (1)Gunma University Graduate School of Medicine, Maebashi, Japan; (2)Takasaki University of Health and Welfare, Faculty of Pharmacy, Takasaki, Japan

188E. Efficacy and safety of desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: Results from 2 placebo-controlled studies.

*Michael Liebowitz, MD*¹, Stuart Montgomery, MD, FRCPsych², Patrice Boyer, MD, PhD³, Amy Manley, MS⁴, Sudharshan Padmanabhan, PhD⁴, Jean-Michel Germain, PhD⁵, Claudine Brisard, MD⁵, Karen Tourian, MD⁵; (1)Columbia University, New York, NY; (2)Imperial College School of Medicine, London, United Kingdom; (3)University of Ottawa, Ontario, ON, Canada; (4)Wyeth Research, Collegeville, PA; (5)Wyeth Research France, Paris, France

189E. Venlafaxine efficacy varies with CYP2D6 phenotype in patients treated for depression.

*Kasia Lobello, MD*¹, Christine Guico-Pabia, MD, MBA, MPH¹, Qin Jiang, MS¹, Alice Nichols, PhD¹, Sheldon

Preskorn, MD²; (1)Wyeth Research, Collegeville, PA; (2)Clinical Research Institute, Wichita, KS

190E. Assessing the pharmacokinetics of venlafaxine ER 75 mg and desvenlafaxine 50 mg in CYP2D6 extensive and Poor metabolizers.

*Cecelia Kane, MD*¹, Alice Nichols, PhD¹, Kristen Focht, MBA¹, Qin Jiang, MS¹, Sheldon Preskorn, MD², Ted Burczynski, PhD¹; (1)Wyeth Research, Collegeville, PA; (2)Clinical Research Institute, Wichita, KS

191E. An open-label pharmacokinetic, safety, and tolerability study of single intravenous doses of ceftaroline in subjects with normal renal function or severe renal impairment.

*Todd Riccobene, PhD*¹, Joseph Laudano, PharmD¹, Ed Fang, MD², Dirk Thye, MD²; (1)Forest Research Institute, Jersey City, NJ; (2)Cereza, Inc, Oakland, CA

192E. Accelerator Mass Spectrometry in Neonatal Clinical Research.

*Le T. Vuong, PhD*¹, Pete Lohstroh, PhD¹, Stephen Dueker, PhD¹, Arlin Blood, PhD², Herbert Vasquez, MD²; (1)Vitalea Science, Inc., Davis, CA; (2)Loma Linda University Children's Hospital, Loma Linda, CA

CLINICAL PHARMACY FORUM

Cardiovascular

226. Utilization of Acute Coronary Syndrome Secondary Prevention Pharmacotherapy at Discharge.

*Lana, YH Lai, Pharmacy*¹, LL Tiong, Pharmacy², Yanti N. Sani, Pharmacy³, Alan, YY Fong, Cardiology⁴, Kamarunnesa MA, Pharmacy⁵, Sameerah SAR, Pharmacy⁶, Kh Sim, Cardiology⁴; (1)Department of Pharmacy, Sibuh Hospital, Sibuh, Malaysia; (2)Department of Pharmacy, Sarawak General Hospital, Kuching, Malaysia; (3)Clinical Research Center, Kuching, Malaysia; (4)Department of Cardiology, Sarawak General Hospital, Kuching, Malaysia; (5)Department of Pharmacy, Serdang Hospital, Serdang, Malaysia; (6)Pharmaceutical Services Division, Ministry of Health, Kuala Lumpur, Malaysia

227. Cost minimization analysis with tirofiban and eptifibatid in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Regan M. Healy, Pharm.D., Matthew W. Call, Pharm.D., Curtis J. McEntire, B.S., Kathryn D. Mathews, Pharm.D., BCPS; Intermountain Medical Center, Murray, UT

228. Evaluation of blood pressure in hypertensive patients following formulary conversion in angiotensin receptor blocker.

Tripti Kurup, Pharm.D., Christina W. Rivers, Pharm.D., BCPS, Todd Lee, Pharm.D., PhD; Edward Hines, Jr. VA Hospital, Hines, IL

Critical Care

234. Development and implementation of a heparin-induced thrombocytopenia pathway in a trauma intensive care unit.

Kathryn A. Connor, Pharm.D., G. Christopher Wood, Pharm.D., Martin A. Croce, M.D., Joseph M. Swanson, Pharm.D., Bradley A. Boucher, Pharm.D., Timothy C. Fabian, M.D.; Regional Medical Center at Memphis/The University of Tennessee Health Science Center, Memphis, TN

235. Evaluation of Process Defects Associated with Delayed Antibiotic Administration in Patients with Severe Sepsis and Septic Shock at a Large Academic Teaching Institution.

*Garrett E. Schramm, Pharm.D.*¹, Kylian S. Kirkham, Pharm.D.², Maria I. Rudis, Pharm.D.¹, Bekele Afessa, MD¹; (1)Mayo Clinic, Rochester, MN; (2)North Dakota State University College of Pharmacy, Fargo, ND

236. High-dose ciprofloxacin for *Enterobacter aerogenes* lumbar osteomyelitis in an obese critically ill patient receiving continuous renal replacement therapy: a case report.

*Theresa R. Utrup, Pharm.D.*¹, Eric W. Mueller, Pharm.D.², Daniel P. Healy, Pharm.D.³, Rachael A. Calcutt, M.D.³, John D. Peterson, D.O.³, William E. Hurford, M.D.³; (1)The University Hospital, Cincinnati, OH; (2)Department of Pharmacy Services, The University Hospital and Division of Pharmacy Practice, University of Cincinnati, Cincinnati, OH; (3)University of Cincinnati, Cincinnati, OH

Education/Training

239. Collaboration between colleges of pharmacy and pharmaceutical industry: A unique relationship.

Colleen M. Moffitt, PharmD, MS, Walter J. McClain, PharmD, BCPS, Scott E. Glosner, PharmD, BCPS, Shannon H. Goldwater, PharmD, BSPS, FASHP; Pfizer, New York, NY

240. Longitudinal research experience during a first year PGY-1 residency program: accomplishments and future directions.

*Michael L. Bentley, Pharm.D., FCCM*¹, Wesley Blankenship, Pharm.D.², Sheri Ober, Pharm.D., BCPS², Megan Goodwin, Pharm.D., BCPS², Corey Goodwin, Pharm.D., BCPS², Jason Hoffman, Pharm.D., BCPS², Amanda Hansen, Pharm.D.²; (1)Carilion Roanoke Memorial Hospital and Virginia Commonwealth

University School of Pharmacy, Roanoke, VA; (2)Carilion Roanoke Memorial Hospital, Roanoke, VA

241. Integration of human patient simulation mannequins into Doctor of Pharmacy curriculum.

Megan Willson, PharmD, Brenda S. Bray, BPharm, MPH, Colleen M. Terriff, PharmD, Mark W. Garrison, PharmD; Washington State University College of Pharmacy, Spokane, WA

242. Integration of pharmacy students into a population based care program to promote the Accreditation Council for Pharmacy Education (ACPE) requirements.

Kristin A. Tuiskula, Pharm.D., Abir O. Kanaan, Pharm.D.; Massachusetts College of Pharmacy and Health Sciences, Worcester, MA

243. Development of online instruction for motivational interviewing.

*Megan Willson, PharmD*¹, Michele A. Packard, PhD², Randall Smith, PhD³, Janice Pringle, PhD³, James Bennett, RPh⁴; (1)Washington State University Spokane, Spokane, WA; (2)Sage Institute, Boulder, CO; (3)University of Pittsburgh, Pittsburgh, PA; (4)James Bennett Apothecary, Corinth, MS

Emergency Medicine

244. Clinical pharmacy services in the emergency department at a level II trauma center.

Bethany S. Delk, Pharm.D., BCPS, Kelli O. Kirkpatrick, Pharm.D., Julie Applegate, Pharm.D., BCPS; Mission Hospitals, Asheville, NC

245. Medication error reports in the emergency department: the impact of emergency medicine pharmacists.

Kyle A. Weant, PharmD, David A. Santrock Jr., PharmD, Roger L. Humphries, MD, Kimberley B. Hite, MS, PharmD, John A. Armitstead, MS, RPh; University of Kentucky HealthCare, Lexington, KY

246. Increased communication improves timeliness of the medication use process.

Ming Poi, Pharm.D, Ph.D, Mary B Shirk, Pharm.D, BCPS; The Ohio State University Medical Center, Columbus, OH

247. Impact of an emergency department antibiogram on out-patient treatment of urinary tract infections.

Eric H. Gilliam, Pharm.D., Kevin O. Rynn, Pharm.D., FCCP, DABAT; Rutgers University Ernest Mario School of Pharmacy, Piscataway, NJ; Robert Wood Johnson University Hospital Emergency Department, New Brunswick, NJ

Infectious Diseases

254. Development and implementation of Geisinger Medical Center's expanded Antimicrobial Stewardship Program.
Carolyn L. Villareal, Pharm.D., BCPS, Dhuha A. Saber, Pharm.D., Kelly M. Bolesta, Pharm.D.; Geisinger Medical Center, Danville, PA

255. Assessment of antimicrobial stewardship activities in a hospital network of smaller hospitals.
Rabiah Dys, PharmD¹, Dimple Patel, PharmD², Jacques Landry, PharmD¹, Marvin Finnefrock, PharmD³, Andrew Lowe, PharmD⁴; (1)Comprehensive Pharmacy Services, Dracut, MA; (2)Comprehensive Pharmacy Services, Edison, NJ; (3)Comprehensive Pharmacy Services, Costa Mesa, CA; (4)Comprehensive Pharmacy Services, Colton, CA

256. Daptomycin for the treatment of Gram-positive bacteremia: 5-year experience at a single center.
Corinne Chahine-Chakhtoura, M.S., Pharm.D., BCPS¹, Manisa Tanprayoon, Pharm.D., BCPS¹, Darren Culshaw, Pharm.D.²; (1)Saint Michael's Medical Center, Newark, NJ; (2)Cubist Pharmaceuticals, Lexington, MA

Pain Management/Analgesia

262E. Dose linearity, consistency, and predictability of plasma concentrations with fentanyl buccal soluble film (FBSF).
Niraj Vasisht, PhD¹, Jeffrey G. Stark, PhD², Andrew L. Finn, PharmD¹, Larry N. Gever, PharmD³; (1)BioDelivery Sciences International, Inc., Raleigh, NC; (2)CEDRA Corporation, Austin, TX; (3)Meda Pharmaceuticals, Inc., Somerset, NJ

Transplant/Immunology

269. Tolerability of de novo maintenance immunosuppressive therapy with sirolimus versus mycophenolic acid in combination with tacrolimus and prednisone Renal Transplant Recipients.
Kwaku Marfo, PharmD, Julie Chen, PharmD, Javier Chapochnik, MD; Montefiore Medical Center, Bronx, NY

RESIDENTS AND FELLOWS RESEARCH IN PROGRESS

Cardiovascular

276. Heparin Dosing Nomograms in Patients Receiving Mechanical Circulatory Assist Devices.
Chaitali J. Desai, PharmD, BCPS¹, A. Janelle Hermsillo, PharmD², Brooke E. Baetz, PharmD, BCPS³, Andrew Peterson, PharmD¹, Mariell Jessup, MD⁴, Rohinton Morris, MD⁴, Sarah A. Spinler, PharmD, FCCP, BCPS¹

(1)University of the Sciences in Philadelphia, Philadelphia, PA; (2)Lehigh Valley Health Network, Lehigh Valley, PA; (3)Penn Presbyterian Medical Center, Philadelphia, PA; (4)Hospital of the University of Pennsylvania, Philadelphia, PA

277. Association between changes in NT-proBNP and clinical outcomes among chronic heart failure patients.
Rachael R. Allwine, Pharm.D.¹, Jessina C. McGregor, PhD², Harleen Singh, Pharm.D.³; (1)Portland VA Medical Center, Portland, OR; (2)Oregon State University/Oregon Health & Science University College of Pharmacy, Portland, OR; (3)Oregon State Univ., College of Pharmacy, Portland, OR

Critical Care

278. Implementation of a real-time, computerized sepsis alerting system in non-ICU medicine patients.
Amber M. Sawyer, PharmD¹, Eli N. Deal, PharmD¹, Andrew J. Labelle, MD², Chad Witt, MD², Steven W. Thiel, MD², Richard M. Reichley, BS¹, Scott T. Micek, PharmD¹, Marin H. Kollef, MD²; (1)Barnes-Jewish Hospital, St. Louis, MO; (2)Washington University School of Medicine, St. Louis, MO

LATE BREAKERS

Critical Care

342. Evaluation of electrolyte serum control after the institution of an electrolyte repletion protocol in a surgical intensive care unit.
Jodianne Couture, M.Sc.(Pharm)¹, Anne Letourneau, M.Sc.(Pharm)¹, Annie Dubuc, M.Sc.(Pharm)¹, Hughes Blain, M.Sc.(Pharm)¹, Julie Perron, M.Sc.(Pharm)¹, Benoit Cossette, M.Sc.¹, David R. Williamson, M.Sc.(Pharm), BCPS²; (1)Centre Hospitalier Universitaire de Sherbrooke, Fleurimont, QC, Canada; (2)Faculté de pharmacie, Université de Montréal, Montreal, QC, Canada

Education/Training

345. Comparative efficacy of conventional teaching methods with and without an active learning exercise in teaching doctor of pharmacy students medication adherence counseling skills.
Kari J. Furtek, Pharm.D., Mark Best, MD, MBA, MPH, Teresa Schweiger, Pharm.D., BCPS, Heather Petrelli, MS, Julie Wilkinson, Pharm.D., BCPS; Lake Erie College of Osteopathic Medicine School of Pharmacy, Bradenton, FL

346E. Clinical interventions by doctor of pharmacy students on advance pharmacy practice experience at a community teaching hospital: acceptance rates and therapeutic areas.

Pamela M. Moye, PharmD, BCPS, Lisa M. Lundquist, PharmD, BCPS, Phillip S. Owen, PharmD, BCPS; Mercer University College of Pharmacy and Health Sciences, Atlanta, GA

Infectious Diseases

350. Clinical experience with daptomycin for the treatment of methicillin-susceptible *Staphylococcus aureus* (MSSA). *Marianne Billeter, PharmD, BCPS¹, Joseph J. Kishel, PharmD², Ellie Hershberger, PharmD², Katherine P Holloway, PharmD²; (1)Ochsner Clinic Foundation, New Orleans, LA; (2)Cubist, Lexington, MA*

351E. Clinical experience with daptomycin for the treatment of vancomycin resistant enterococcal bacteremia (VRE-B).

Monica M. Gaffney, PharmD¹, Peggy S. McKinnon, PharmD¹, John F. Mohr, PharmD¹, Marcus J. Zervos, M.D.²; (1)Cubist, Lexington, MA; (2)Henry Ford Health System and Wayne State University School of Medicine, Detroit, MI

352E. Outcomes with daptomycin in the treatment of *Staphylococcus aureus* infections with varying vancomycin minimum inhibitory concentrations.

Jason A. Crompton, PharmD, Donald S. North, PharmD, MinJung Yoon, MPH, Judith N. Steenberg, PhD, Kenneth C. Lamp, PharmD; Cubist Pharmaceuticals, Lexington, MA

353. Potential impact of medications on clostridium difficile toxin screening and cultures.

Jean A. Patel, PharmD, BCPS¹, Marc H. Scheetz, PharmD, MSc, BCPS², Michael J. Postelnick, RPh, BCPS¹; (1)Northwestern Memorial Hospital, Department of Pharmacy, Chicago, IL; (2)Midwestern University, Department of Pharmacy Practice, Chicago, IL

Pharmacokinetics/Pharmacodynamics/Drug

361. Assessing the effect of Roux-en-Y gastric bypass on CYP3A activity.

Lingtak-Neander Chan, PharmD, BCNSP¹, Yvonne S. Lin, PhD², Brant K. Oelschlager, MD³, David R. Flum, MD, MPH³, Danny D. Shen, PhD¹, John R. Horn, PharmD¹, Edward J. Kelly, PhD², Rodney J.Y. Ho, PhD²; (1)University of Washington, Department of Pharmacy, Seattle, WA; (2)University of Washington, Department of Pharmaceutics, Seattle, WA; (3)University of Washington, Department of Surgery, Seattle, WA

362. Effect of proximal Roux-en-Y gastric bypass on oral bioavailability of P-glycoprotein substrates.

Lingtak-Neander Chan, PharmD, BCNSP¹, Yvonne S. Lin, PhD², Brant K. Oelschlager, MD³, David R. Flum, MD, MPH³, Kristen K. Patton, MD⁴, Danny D. Shen,

PhD¹, John R. Horn, PharmD¹, Rodney J.Y. Ho, PhD², Edward J. Kelly, PhD¹; (1)University of Washington, Department of Pharmacy, Seattle, WA; (2)University of Washington, Department of Pharmaceutics, Seattle, WA; (3)University of Washington, Department of Surgery, Seattle, WA; (4)University of Washington, Department of Medicine, Seattle, WA

363. Daptomycin plasma concentrations during cardiopulmonary bypass: a prospective, open-label pharmacokinetic investigation.

Megan H. Nguyen, Pharm.D.¹, Samantha J. Eells, M.P.H.², Jennifer Tan, M.H.S.², Bassam O. Omari, M.D.³, Tina Sheth, M.D.³, Loren G. Miller, M.D., M.P.H.³; (1)Western University of Health Sciences, Pomona, CA; (2)Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; (3)Harbor-UCLA Medical Center, Torrance, CA